Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study-Reference-Cited by-同舟云学术

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study

Published:2013-12-11 Issue:2 Volume:54 Page:168-178
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Padhi Desmond¹,Allison Mark²,Kivitz Alan J.³,Gutierrez Maria J.⁴,Stouch Brian¹,Wang Christine¹,Jang Graham¹

Affiliation:

1. Amgen Inc.; Thousand Oaks CA USA

2. MDS Pharma Services (US), Inc.; Tempe AZ USA

3. Altoona Center for Clinical Research; Duncansville PA USA

4. Comprehensive Phase One; Miramar FL USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.239/fullpdf

Reference18 articles.

1. http://www.nof.org/advocacy/resources/prevalencereport 2012

2. Sclerostin: a gem from the genome leads to bone-building antibodies;Paszty;J Bone Miner Res.,2010

3. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein;Brunkow;Am J Hum Genet.,2001

4. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST);Balemans;Hum Mol Genet.,2001

5. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength;Li;J Bone Miner Res.,2008

Cited by 155 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Relationship between Sclerostin and Kidney Transplantation Mineral Bone Disorders: A Molecule of Controversies;Calcified Tissue International;2024-07-30

2. Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury;JBMR Plus;2024-05-31

3. WISH-BONE: Whole-mount In Situ Histology, to label osteocyte mRNA and protein in 3D adult mouse bones;2024-03-15

4. Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study;JBMR Plus;2024-02-07

5. Τhe story of sclerostin inhibition: the past, the present, and the future;Hormones;2024-01-03